

Fig. 2




Fig. 3




Fig. 4




Fig. 5

Pharmaceutical Product: Diabetes Drug

Object Patent: USP 7,100,100

Regulatory Approving Data					
M1	Accessibility	✓			
M2	Development Cost	US\$10,000,000			
	Phase of Development	Pre-Clinical	Phase I	Phase II	Phase III
M3	Amount of Lump-Sum	-	US\$2,000,000	US\$5,000,000	US\$7,500,000
M4	Ratio of Lump-Sum	-	20%	50%	75%
M5	Ratio of Sales	-	0.30%	0.50%	1.00%
M6	Amount of Running/y	-	US\$100,000	US\$200,000	US\$300,000
M7	Ratio of Running/y	-	0.10%	0.20%	0.30%
M8	Ratio of Sales Running/y	-	0.20%	0.40%	0.60%

Fig. 6

Pharmaceutical Product:

Diabetes Drug

Patent Number	Title	Owner	Jurisdictions
USP 7,100,100	Medicament for diabetes	A	United States
EP 1100100	Diabetes management system	C	Europe
JP 3,000,001	Medicament for the treatment of diabetes	B	Japan
USP 7,200,200	Compounds to treat diabetes	A	United States
JP 3,000,002	Device for treating diabetes and methods thereof	B	Japan
USP 7,300,300	Medicament for complications of type 2 diabetes	A	United States
EP 1200200	Medicament for treatment of type I diabetes	C	Europe




Fig. 8

Pre-Marketing Approval Process

